behnoosh mohammadi-jazi

One of the most important factors in determining prognosis and therapeutic plan in patients with breast cancer is tumor size. Our aim in this study was to compare the estimated tumor size in two common imaging modalities, ultrasound and mammography with pathologic assessment.

In this cross sectional study, we analyzed 287 patients with breast cancer diagnosis whose pathologic specimen was reported in pathology department of Omid hospital (Isfahan, Iran) from March 2015 to March 2020. The difference in tumor size were evaluated based on imaging and pathological reports. Then, we classified them in three groups as concordant, underestimated, and overestimated for which the effect of various factors such as age, tumor type, T stage and molecular subtype on accuracy of each modality was assessed.

Concordance rate was 58.3% in ultrasonography and 51.7% in mammography. Ultrasonography and mammography respectively underestimated the tumor size in 30.6% and 31%, and overestimated in 11.1% and 17.2% of cases indicating no statistically significant difference between the two modalities. Ultrasonography and mammography underestimate large tumors more commonly than small tumors. For tumors smaller than 20 mm and HER2- tumors, ultrasonography is more accurate than mammography. Also, mammography estimates the size of Luminal A tumors compared to ultrasound.

There was no significant difference between the accuracy of ultrasonography and mammography measurement of tumor size, but inherent factors such as T stage, her2 expression and molecular subtype influence this issue.

Salivary gland tumors are relatively uncommon. These tumors may occur in both major and minor salivary glands. The aim of this study was to evaluate the relative frequency of salivary gland tumors in patients referred to Alzahra hospital, Isfahan, Iran, during 2009-2019.

This study was a cross-sectional study. To collect the required information, salivary gland tumors registered in the pathology department of Alzahra hospital from April 2009 to April 2019 were examined, and the patient's demographic data including age, sex, and pathological information of the tumor including tumor type, location, lymph node involvement, vascular invasion, and perineural invasion were collected.

The total number of patients was 186 with age range of 14 to 79 years (mean 42.49 ±14.37), of which 94 (50.5%) were women and 92 (49.5%) were men. The frequency of benign and malignant tumors was 67% and 33%, respectively. The mean age of patients with benign and malignant tumors was 43.54 and 51.65 years, respectively. There were 110 patients (59.1%) with pleomorphic adenoma, 13 (7.0%) with warthin tumor, 40 (21.5%) with mucoepidermoid carcinoma, 8 (4.3%) with adenoid cystic carcinoma, 11 (5.9%) with acinic cell carcinoma, 3 (1.6%) with malignant mixed tumor, and 1 (0.5%) with myoepithelioma.

According to our findings, pleomorphic adenoma and then warthin tumor were the most common benign tumors, and mucoepidermoid carcinoma was the most common malignant tumor. The most common site of involvement was the parotid salivary gland.

Thyroid carcinoma is the most common endocrine cancer. There are several methods for determining the mutation of genes, one of them is random amplified polymorphic DNA polymerase chain reaction (RAPD-PCR). This study aimed to compare DNA changes in the genome of thyroid hyperplasia, thyroid papillary carcinoma, and healthy tissues using RAPD-PCR. In this case-control study, 49 patients with papillary carcinoma and thyroid hyperplasia which had normal, hyperplasia, and papillary carcinoma tissues of the thyroid gland were randomly selected. Then, the primer pattern of the sequence 5'-AAGAGCCCGT-3' containing 10 pairs base was evaluated and compared between the tissues. The prevalence of 370-bp pair base band observed in normal, hyperplasia, and pylori thyroid carcinoma tissues was 6.1, 53.1, and 89.8 percent, respectively, and there was a significant difference between the three tissue types (P < 0.001). There was also a significant difference between normal tissue with hyperplasia and papillary carcinoma of the thyroid and between hyperplasia with thyroid carcinoma in this regard (P < 0.050). It seems that using RAPD-PCR is a suitable method for the detection and differentiation of normal, hyperplasia, and papillary thyroid carcinoma cells. Bat notice to the limitation of the study, more investigation in this field is recommended.